Intracerebroventricular fluvoxamine administration inhibited pain behavior but increased Fos expression in affective pain pathways

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 3, 2009, Pages 441-446

  Hayashi, Takayuki ^a   Miyata, Mariko ^a   Nagata, Tomonari ^a   Izawa, Yumi ^a   Kawakami, Yoriko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Amygdala; Nociception; Prefrontal cortex

Indexed keywords

FLUVOXAMINE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROTEIN FOS; SEROTONIN 2 RECEPTOR;

ALLODYNIA; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PAIN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR UPREGULATION;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; FLUVOXAMINE; FORMALDEHYDE; GENE EXPRESSION; GENES, FOS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; NEURAL PATHWAYS; PAIN; PAIN MEASUREMENT; RECEPTORS, SEROTONIN; SCIATIC NEUROPATHY; SEROTONIN UPTAKE INHIBITORS;

EID: 57449109990     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.08.029     Document Type: Article

References (65)

1. Aggleton J.P., and Saunders R.C. The amygdala - what's happened in the last decade. In: Aggleton, and J.P. (Ed). The Amygdala (2000), Oxford University Press, Oxford 1-31
2. Anjaneyulu M., and Chopra K. Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. Eur J Pharmacol 497 (2004) 285-292
3. Bacon S.J., Headlam A.J., Gabbott P.L., and Smith A.D. Amygdala input to medial prefrontal cortex (mPFC) in the rat: a light and electron microscope study. Brain Res 720 (1996) 211-219
4. Bernard J., Bester H., and Besson J. Involvement of the spino-parabrachio-amygdaloid and -hypothalamic pathways in the autonomic and affective emotional aspects of pain. Prog Brain Res 107 (1996) 243-255
5. Blumer D., Heilbronn M., Pedraza E., and Pope G. Systematic treatment of chronic pain with antidepressants. Henry Ford Hosp Med J 28 (1980) 15-21
6. Bonnefont J., Chapuy E., Clottes E., Alloui A., and Eschalier A. Spinal 5-HT1A receptors differentially influence nociceptive processing according to the nature of the noxious stimulus in rats: effect of WAY-100635 on the antinociceptive activities of paracetamol, venlafaxine and 5-HT. Pain 114 (2005) 482-490
7. Buffington A., Hanlon C., and McKeown M. Acute and persistent pain modulation of attention-related anterior cingulate fMRI activations. Pain 113 (2005) 172-184
8. Bundgaard C., Larsen F., Jørgensen M., and Gabrielsson J. Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. Eur J Pharm Sci 29 (2006) 394-404
9. Büchel C., Bornhovd K., Quante M., Glauche V., Bromm B., and Weiller C. Dissociable neural responses related to pain intensity, stimulus intensity, and stimulus awareness within the anterior cingulate cortex: a parametric single-trial laser functional magnetic resonance imaging study. J Neurosci 22 (2002) 970-976
10. Cassell M.D., and Wright D.J. Topography of projections from the medial prefrontal cortex to the amygdala in the rat. Brain Res Bull 17 (1986) 321-333
11. Clark M., and Treisman G. Perspectives on pain and depression. Adv Psychosom Med 25 (2004) 1-27
12. Davis M. The role of the amygdala in conditioned and unconditioned fear and anxiety. In: Aggleton J.P. (Ed). Amygdala (2001), Oxford Press, Oxford 213-288
13. Evans W. The use of antidepressants, anticonvulsants and neuroleptic drugs in treating pain. Indiana Med 78 (1985) 491-493
14. France R., Houpt J., and Ellinwood E. Therapeutic effects of antidepressants in chronic pain. Gen Hosp Psych 6 (1984) 55-63
15. Fu C.Y., Yang Q., Wang K.R., Kong Z.Q., Chen Q., and Wang R. Rat/mouse hemokinin-1, a mammalian tachykinin peptide, markedly potentiates the antinociceptive effects of morphine administered at the peripheral and supraspinal level. Behav Brain Res 170 (2006) 293-301
16. Gao Y., Ren W., Zhang Y., and Zhao Z. Contributions of the anterior cingulate cortex and amygdala to pain- and fear-conditioned place avoidance in rats. Pain 110 (2004) 343-353
17. Goldstein D., Lu Y., Detke M., Hudson J., Iyengar S., and Demitrack M. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45 (2004) 17-28
18. Gordon D., and Love G. Pharmacologic management of neuropathic pain. Pain Manag Nurs 5 (2004) 19-33
19. Gronier B., and Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Lett 349 (2003) 196-200
20. Haley T., and McCormick W. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12 (1957) 12-15
21. Harris R.A., Loh H.H., and Way E.L. Effects of divalent cations, cation chelators and an ionophore on morphine analgesia and tolerance. J Pharmacol Exp Ther 195 (1975) 488-498
22. Herman Z.S. Behavioural changes induced in conscious mice by intracerebroventricular injection of catecholamines, acetylcholine and 5-hydroxytryptamine. Br J Pharmacol 55 (1975) 351-358
23. Honda M., Uchida K., Tanabe M., and Ono H. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology 51 (2006) 866-872
24. Izawa Y., and Kawakami Y. Prolonged depression of nociceptive response in the prefrontal cortex with high frequency stimulation of the amygdala. Neurosci Res 55 (2006) 190
25. Izumi T., Inoue T., Kitaichi Y., Nakagawa S., and Koyama T. Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. Eur J Pharmacol 534 (2006) 129-132
26. Janusonis S., and Fite K.V. Diurnal variation of c-Fos expression in subdivisions of the dorsal raphe nucleus of the Mongolian gerbil (Meriones unguiculatus). J Comp Neurol 440 (2001) 31-42
27. Jasmin L., Burkey A., Card J., and Basbaum A. Transneuronal labeling of a nociceptive pathway, the spino-(trigemino-)parabrachio-amygdaloid, in the rat. J Neurosci 17 (1997) 3751-3765
28. Jensen J., Jessop D., Harbuz M., Mørk A., Sánchez C., and Mikkelsen J. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol 11 (1999) 465-471
29. Jones C., Peters S., and Shannon H. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312 (2005) 726-732
30. Jongsma M., Sebens J., Bosker F., and Korf J. Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain. Eur J Pharmacol 455 (2002) 109-115
31. Jung A., Staiger T., and Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 12 (1997) 384-389
32. Kawahara H., Yoshida M., Yokoo H., Nishi M., and Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett 162 (1993) 81-84
33. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16 (1986) 355-357
34. Lépine J., and Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 19 Suppl 1 (2004) S3-7
35. Macedo C., Martinez R., de Souza Silva M., and Brandão M. Increases in extracellular levels of 5-HT and dopamine in the basolateral, but not in the central, nucleus of amygdala induced by aversive stimulation of the inferior colliculus. Eur J Neurosci 21 (2005) 1131-1138
36. Maroun M., and Richter-Levin G. Exposure to acute stress blocks the induction of long-term potentiation of the amygdala-prefrontal cortex pathway in vivo. J Neurosci 23 (2003) 4406-4409
37. Mattia C., and Coluzzi F. Antidepressants in chronic neuropathic pain. Mini Rev Med Chem 3 (2003) 773-784
38. McDonald A. Cortical pathways to the mammalian amygdala. Prog Neurobiol 55 (1998) 257-332
39. Mena N., Mathur R., and Nayar U. Amygdalar involvement in pain. Indian J Physiol Pharmacol 39 (1995) 339-346
40. Merskey H., and Hester R. The treatment of chronic pain with psychotropic drugs. Postgrad Med J 48 (1972) 594-598
41. Morelli M., Pinna A., Ruiu S., and Del Zompo M. Induction of Fos-like-immunoreactivity in the central extended amygdala by antidepressant drugs. Synapse 31 (1999) 1-4
42. Nakagawa T., Katsuya A., Tanimoto S., Yamamoto J., Yamauchi Y., Minami M., et al. Differential patterns of c-fos mRNA expression in the amygdaloid nuclei induced by chemical somatic and visceral noxious stimuli in rats. Neurosci Lett 344 (2003) 197-200
43. Narita M., Kaneko C., Miyoshi K., Nagumo Y., Kuzumaki N., Nakajima M., et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31 (2006) 739-750
44. Nemoto H., Toda H., Nakajima T., Hosokawa S., Okada Y., Yamamoto K., et al. Fluvoxamine modulates pain sensation and affective processing of pain in human brain. Neuroreport 14 (2003) 791-797
45. Ohashi S., Matsumoto M., Otani H., Mori K., Togashi H., Ueno K., et al. Changes in synaptic plasticity in the rat hippocampo-medial prefrontal cortex pathway induced by repeated treatments with fluvoxamine. Brain Res 949 (2002) 131-138
46. Pan W., Hsuchou H., and Kastin A.J. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 28 (2007) 2223-2228
47. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. 2nd ed. (2001), Academic Press, San Diego
48. Petitto J., Mundle L., Nagy B., Evans D., and Golden R. Improvement of arthritis with fluoxetine. Psychosomatics 33 (1992) 338-341
49. Price D. Psychological and neural mechanisms of the affective dimension of pain. Science 288 (2000) 1769-1772
50. Rainville P., Duncan G., Price D., Carrier B., and Bushnell M. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 277 (1997) 968-971
51. Rani P., Naidu M., Prasad V., Rao T., and Shobha J. An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg 83 (1996) 371-375
52. Shimodozono M., Kawahira K., Kamishita T., Ogata A., Tohgo S., and Tanaka N. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 112 (2002) 1173-1181
53. Sikes R., and Vogt B. Nociceptive neurons in area 24 of rabbit cingulate cortex. J Neurophysiol 68 (1992) 1720-1732
54. Silva E., and Hernández L. Extracellular aminoacids in the amygdala and nucleus accumbens in the rat during acute pain. Invest Clin 48 (2007) 213-224
55. Silverstrini B., and Lisciani R. Pharmacology of trazodone. Curr Ther Res Clin Exp 15 (1973) 749-754
56. Simpson J.J., Drevets W., Snyder A., Gusnard D., and Raichle M. Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. Proc Natl Acad Sci U S A 98 (2001) 688-693
57. Sumpton J., and Moulin D. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 35 (2001) 557-559
58. Sánchez-Blázquez P., García-España A., and Garzón J. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. J Pharmacol Exp Ther 275 (1995) 1590-1596
59. Taylor K., and Rowbotham M. Venlafaxine hydrochloride and chronic pain. West J Med 165 (1996) 147-148
60. Veening J., Coolen L., Spooren W., Joosten H., van Oorschot R., Mos J., et al. Patterns of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration. Eur Neuropsychopharmacol 8 (1998) 213-226
61. Vogt BA. Anterior Cingulated Cortex and the Medial Pain System (1993), Birkhauser, Boston
62. Wilson R. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc 89 (1999) 468-471
63. Yokoyama M., Suzuki E., Sato T., Maruta S., Watanabe S., and Miyaoka H. Amygdalic levels of dopamine and serotonin rise upon exposure to conditioned fear stress without elevation of glutamate. Neurosci Lett 379 (2005) 37-41
64. Zhang R., Nagata T., Hayashi T., Miyata M., and Kawakami Y. Intracerebroventricular injection of trazodone produces 5-HT receptor subtype mediated anti-nociception at the supraspinal and spinal levels. Eur Neuropsychopharmacol 14 (2004) 419-424
65. Zhang R., Tomida M., Katayama Y., and Kawakami Y. Response durations encode nociceptive stimulus intensity in the rat medial prefrontal cortex. Neuroscience 125 (2004) 777-785